1Nathan DM,Bnse JB,Davidson MB. Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2009.193-203.
2Wright A,Burden AC,Paise RB. Sulfonylurea inadequacy:efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K.Prospective Diabetes Study (UKPDS 57)[J].Diabetes Care,2002,(2):330-336.doi:10.2337/diacare.25.2.330.
3Brange J,Owens DR,Kang S. Monomeric insulins and their experimental and clinical implications[J].Diabetes Care,1990.923-954.
4Weyer C,Heise T,Heinemann L. Insulin aspart in a 30/70 premixed formulation:pharmacodynamic properties of a rapidacting insulin analog in stable mixture[J].DIABETES CARE,1997.1612-1614.
5Raskin R Allen E;Hollander P.Initiating insulin therapy in type 2 diabetes:a comparison of biphasic and basal insulin analogs[J]Diabetes Care,2005(02):260-265.
6Yang W,Ji Q,Zhu D. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen.without increasing hypoglycemia,in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs[J].Diabetes Care,2008.852-856.
7Yang W,Can Y,Liu G. Biphasic insulin aspart 30 as insulin initiation or replacement therapy:the China cohort of the IMPROVE study[J].Current Medical Research and Opinion,2010.101-107.doi:10.1185/03007990903364640.
8Unnikrishnan AG,Tibaldi J,Hadley-Brown M. Practical guidance on intensification of insulin therapy with BIAsp 30:a consensus statement[J].International Journal of Clinical Practice,2009,(11):1571-1577.doi:10.1111/j.1742-1241.2009.02192.x.
9Garber AJ,Wahlen J,wahl T. Attainment of glycaemic goals in type 2 diabetes with once-,twice-,or thrice-daily dosing with biphasic insulin aspart 70/30(The 1-2-3 study)[J].Diabetes,Obesity and Metabolism,2006,(1):58-66.doi:10.1111/j.1463-1326.2005.00563.x.
10Lund SS,Tarnow L,Nielsen BB. Efficacy and safety of BIAsp 30(Biphasic insulin aspart 30)TID in combination with oral hypoglycaemic agents in non-obese patients with type 2 diabetes[J].Diabetologia,2007.S409.
